

Financial news for NAVB dated on 2020-06-03: Navidea Biopharmaceuticals Announces Acceptance Of Abstract For Presentation At The European League Against Rheumatism (EULAR) Congress

Financial news for NAVB dated on 2020-05-26: 28 Stocks Moving in Tuesday's Pre-Market Session

Financial news for NAVB dated on 2020-05-26: 71 Biggest Movers From Friday

Financial news for NAVB dated on 2020-05-22: Mid-Afternoon Market Update: NASDAQ Turns Higher; Hewlett Packard Shares Tumble

Financial news for NAVB dated on 2020-05-22: HC Wainwright & Co. Maintains Buy on Navidea Biopharmaceutical, Raises Price Target to \$6

Financial news for NAVB dated on 2020-05-22: 46 Stocks Moving In Friday's Mid-Day Session

Financial news for NAVB dated on 2020-05-22: Mid-Day Market Update: LiveRamp Surges Following Q4 Results; Syndax Pharmaceuticals Shares Plummet

Financial news for NAVB dated on 2020-05-22: H.C. Wainwright Reiterates Buy On Navidea Biopharmaceuticals, Raises Price Target From \$4 To \$6; Says 'Interim results further support tilmanocept's potential for use in RA quantitative imaging. '

Financial news for NAVB dated on 2020-05-22: Mid-Morning Market Update: Markets Fall; Alibaba Earnings Beat Estimates

Financial news for NAVB dated on 2020-05-22: 30 Stocks Moving in Friday's Pre-Market Session

Financial news for NAVB dated on 2020-05-22: The Daily Biotech Pulse: FDA Nod For Aquestive, Tetrphase M&A Plot Thickens, Amarin's Vascepa In COVID Fray

Financial news for NAVB dated on 2020-05-21: Navidea Biopharmaceuticals Announces Results Of Second Interim Analysis Of Ongoing Phase 2B Study In Rheumatoid Arthritis

Financial news for NAVB dated on 2020-05-14: Navidea Biopharmaceutical Q1 EPS \$(0.130) Up From \$(0.240) YoY, Sales \$156.272K Up From \$136.032K YoY

Financial news for NAVB dated on 2020-05-14: The Daily Biotech Pulse: ASCO Abstracts Create Stock Ripples, Applied DNA's Coronavirus Test Receives EUA, Biopharmx Shareholders Vet Reverse Merger

Financial news for NAVB dated on 2020-05-11: Navidea Biopharmaceuticals Regains Commercialization And Distributions Rights In Europe For LYMPHOSEEK

Financial news for NAVB dated on 2020-05-10: The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight

Financial news for NAVB dated on 2020-03-31: Navidea Biopharmaceuticals Signs Letter Of Intent With WorldCare Clinical To Partner On Navidea's Rheumatoid Arthritis Clinical Imaging Workflow And Commercialization

Financial news for NAVB dated on 2020-03-20: Navidea Biopharma Reports Issuance Of Patent Extension For Lymphoseek For Added 5 Years Through May 12, 2025

Financial news for NAVB dated on 2020-03-11: Navidea Biopharmaceutical Q4 EPS \$(0.15) Misses \$(0.12) Estimate, Sales \$119.299K Down From \$119.321K YoY

Financial news for NAVB dated on 2020-03-11: The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment

Financial news for NAVB dated on 2020-03-08: The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues

Financial news for NAVB dated on 2020-03-02: H.C. Wainwright Reiterates Buy on Navidea Biopharmaceutical, Raises Price Target to \$4

Financial news for NAVB dated on 2020-02-14: Navidea Biopharma Reports Regained NYSE American Compliance

Financial news for NAVB dated on 2020-02-14: Navidea Biopharma Shares Halted

Financial news for NAVB dated on 2020-02-14: Navidea Biopharma Reports \$4.2M Sale Of Ohio Court Judgment, \$3.4M Equity Raise For \$7.6M In Added Funding

Financial news for NAVB dated on 2019-12-30: Navidea Biopharmaceuticals Obtains Partial Dismissal of Claims in New York

Financial news for NAVB dated on 2019-12-02: Navidea Biopharmaceuticals Shares Resume Trade, Up 33% at \$1.18

Financial news for NAVB dated on 2019-12-02: Navidea Biopharmaceuticals Wins Summary Judgment in Ohio

Financial news for NAVB dated on 2019-12-02: Navidea Biopharmaceuticals Shares Halted, News Pending

Financial news for NAVB dated on 2019-11-22: H.C. Wainwright Initiates Coverage On Navidea Biopharmaceutical with Buy Rating, Announces \$3 Price Target

Financial news for NAVB dated on 2019-11-07: Navidea Biopharmaceutical Q3 Sales \$236.811K Up From \$231.458K YoY

Financial news for NAVB dated on 2019-11-07: Navidea Biopharmaceuticals Earlier Announced Announce Preclinical Therapeutic Research Collaboration With IMV Inc. To Explore Potential Combinatory Effect With Their Platform-Based Immunotherapies

Financial news for NAVB dated on 2019-11-07: The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs

Financial news for NAVB dated on 2019-10-29: Navidea Biopharma Reports Results From First Interim Analysis Of Ongoing Phase 2B Study In RA: Showed Quantitative Repeatability, Stability Of Signal

Financial news for NAVB dated on 2019-08-08: Navidea Biopharmaceutical Q2 EPS \$(0.24) Down From \$(0.02) YoY, Sales \$206K May Not Compare To \$542.127K YoY

Financial news for NAVB dated on 2019-07-12: Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Friday, July 12, 2019

Financial news for NAVB dated on 2019-07-12: 55 Biggest Movers From Yesterday

Financial news for NAVB dated on 2019-07-11: Top 10 Most Oversold Stocks Via Benzinga Pro's Radar Tool For Thu., July 11, 2019

Financial news for NAVB dated on 2019-07-11: 48 Stocks Moving In Thursday's Mid-Day Session

Financial news for NAVB dated on 2019-07-11: What Caused The Opening Gap In Navidea Biopharmaceuticals?

Financial news for NAVB dated on 2019-07-11: Navidea Biopharmaceuticals shares are trading higher after Maxim Group initiated coverage on the stock with a Buy rating.

Financial news for NAVB dated on 2019-07-11: Navidea Biopharma Shares Up 68% Premarket; Hearing Maxim Set \$2 Price Target On Stock

Financial news for NAVB dated on 2019-07-11: Maxim Group Initiates Coverage On Navidea Biopharmaceutical with Buy Rating

Financial news for NAVB dated on 2019-06-22: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs

Financial news for NAVB dated on 2019-06-17: 46 Biggest Movers From Friday

Financial news for NAVB dated on 2019-06-14: Mid-Afternoon Market Update: Dow Turns Positive; India Globalization Capital Shares Spike Higher

Financial news for NAVB dated on 2019-06-14: 35 Stocks Moving In Friday's Mid-Day Session

Financial news for NAVB dated on 2019-06-14: Mid-Day Market Update: Renren Drops After Q1 Results; ArQule Shares Surge

Financial news for NAVB dated on 2019-06-14: The Daily Biotech Pulse: Hematology And Rheumatology Conference Presentations Take The Spotlight, Eton In-Licenses Epilepsy Drug NDA

Financial news for NAVB dated on 2019-06-14: Navidea Biopharmaceuticals shares are trading lower after the company announced a common stock offering of 8 million shares at \$0.75 per share.

Financial news for NAVB dated on 2019-06-14: 26 Stocks Moving In Friday's Pre-Market Session

Financial news for NAVB dated on 2019-06-14: Navidea Biopharmaceuticals Prices 8M

Share Public Offering of Common Stock @\$0.75/Share

Financial news for NAVB dated on 2019-06-13: Navidea Biopharmaceuticals Reports Common Stock Offering; Size Not Disclosed

Financial news for NAVB dated on 2019-06-13: Navidea Biopharmaceuticals shares are trading higher after the company regained direct control of Intellectual Property.

Financial news for NAVB dated on 2019-06-13: Navidea Biopharmaceuticals Regains Direct Control Of Intellectual Property

Financial news for NAVB dated on 2019-06-13: The Daily Biotech Pulse: Savara Slumps On Flunked Trial, NuCana Takes Off, Tetrphase Downsizes

Financial news for NAVB dated on 2019-06-07: The Daily Biotech Pulse: Vertex Bets Big On Gene-Editing Therapies, Sanofi Poaches Novartis For CEO Role, Relief In Europe for Endologix

Financial news for NAVB dated on 2019-05-08: Navidea Biopharmaceutical Q1 EPS \$(0.24) Up From \$(0.83) YoY, Sales \$136.032K Down From \$276.445K YoY

Financial news for NAVB dated on 2019-04-29: 48 Biggest Movers From Friday

Financial news for NAVB dated on 2019-04-26: Navidea Biopharmaceuticals Announces Comparative Study to Evaluate The Potential Utility of Tilmanocept In Patients with Tuberculosis ("TB")

Financial news for NAVB dated on 2019-04-09: 50 Biggest Movers From Yesterday

Financial news for NAVB dated on 2019-04-08: Navidea Biopharma 8-K Shows Co. Received NYSE American Notice Related To Non Compliance With \$2M Minimum Shareholder Equity Requirement; Co. Has Until Apr. 15, 2019 To Be Considered For Continued Trading

Financial news for NAVB dated on 2019-04-08: Mid-Afternoon Market Update: Art's-Way Manufacturing Drops After Q1 Results; Navidea Biopharmaceuticals Shares Climb

Financial news for NAVB dated on 2019-04-08: Mid-Day Market Update: Crude Oil Up 1.7%; BP Prudhoe Bay Royalty Trust Shares Plunge

Financial news for NAVB dated on 2019-04-08: 48 Stocks Moving In Monday's Mid-Day Session

Financial news for NAVB dated on 2019-04-08: Navidea Biopharmaceuticals shares are trading higher after the company reported it received FDA feedback related to its Rheumatoid Arthritis trial for Phase 2B and the FDA said it would continue to work with the company for Phase 3 Trial.

Financial news for NAVB dated on 2019-04-08: UPDATE: Navidea Says Is Prepared To Initiate Phase 3 Study, NAV3-31

Financial news for NAVB dated on 2019-04-08: Navidea Biopharma Reports Received FDA Feedback Related to Rheumatoid Arthritis Trial Design: FDA Said First Study, Phase 2b Trial, Is Aligned With Expectations For Studies, Will Continue To Work With Co. For Phase 3 Trial

Financial news for NAVB dated on 2019-04-02: Navidea Biopharma Reports Will Present Results Of NAV3-21 Study At SNMMI Meeting In Jun. 2019

Financial news for NAVB dated on 2019-03-25: Navidea Biopharmaceuticals shares are trading higher after the company announced a \$3M stock purchase agreement with an existing investor.

Financial news for NAVB dated on 2019-03-22: Navidea Biopharma Reports \$3M Private Placement

Financial news for NAVB dated on 2019-03-07: Daily Biotech Pulse: Allergan's Depression Drug Flunks Late-Stage Trial, Apellis Offering, ShockWave Medical IPO

Financial news for NAVB dated on 2019-02-28: Patterson Companies Sees FY19 Adj. EPS \$1.40-\$1.45

Financial news for NAVB dated on 2019-02-01: Navidea Biopharma Reports Extension Of NYSE American Listing Until Mar. 31, 2019 To Regain Compliance

Financial news for NAVB dated on 2019-01-24: Navidea Biopharma Announces the Ohio Supreme Court has Dismissed a Petition Filed by Capital Royalty Partners

Financial news for NAVB dated on 2018-12-07: Navidea Biopharma Reports Patent Extension For Lymphoseek For Added 5 Yers To May 12, 2025

Financial news for NAVB dated on 2018-11-07: Navidea Biopharmaceutical Q3 EPS \$(0.02) Down From \$(0.01) YoY, Sales \$231.458K Up From \$223.669K YoY

Financial news for NAVB dated on 2018-11-02: Navidea Biopharma Shares Resume Trade, Now Up 4%

Financial news for NAVB dated on 2018-11-02: UPDATE: Navidea Says Court Granted Motion To Dismiss, Directed Judgement In Favor Of Co.

Financial news for NAVB dated on 2018-11-02: UPDATE: Navidea Says Court Disagreed With Platinum-Montaur Claim Of Unjust Enrichment On Similar Grounds, Found Firm 'lacked any sufficient personal stake to maintain claims against Navidea'

Financial news for NAVB dated on 2018-11-02: UPDATE: Navidea Biopharma Filing Shows Court Rejected Platinum-Montaur Claim That Assignment Of Co. Note Was Partial Assignment, Found 'Assignment Agreement unambiguously assigned the entirety of Platinum-Montaur's interest in the Navidea debt to PPCO'

Financial news for NAVB dated on 2018-11-02: Navidea Biopharma 8-K Shows Platinum-Montaur Asserted Its Assignment To PPCO Was Only A Partial Assignment, \$1.5M Remained Due, Owing to Platinum-Montaur

Financial news for NAVB dated on 2018-11-02: Navidea Biopharmaceuticals Shares Halted, News Pending

Financial news for NAVB dated on 2018-10-31: Navidea Biopharmaceuticals Reports Court Dismisses Claims Against Co. By Platinum-Montaur Life Sciences

Financial news for NAVB dated on 2018-10-30: Navidea Biopharmaceuticals Receives Acceptance Letter from NYSE American, Common Stock Will Continue To Be Listed

Financial news for NAVB dated on 2018-09-19: 60 Biggest Movers From Yesterday

Financial news for NAVB dated on 2018-09-18: 44 Stocks Moving In Tuesday's Mid-Day Session

Financial news for NAVB dated on 2018-09-18: Mid-Morning Market Update: Markets Open Higher; AutoZone Profit Tops Views

Financial news for NAVB dated on 2018-09-18: The Daily Biotech Pulse: Morphosys Expands Collaboration, Osiris Announces Product Launch, Argenx To Offer Shares

Financial news for NAVB dated on 2018-09-18: 22 Stocks Moving In Tuesday's Pre-Market Session

Financial news for NAVB dated on 2018-09-17: Navidea Biopharmaceuticals shares are up 16.3% after the company reported acceptance into the National Institutes of Health Commercialization Accelerator Program.

Financial news for NAVB dated on 2018-09-17: Navidea Biopharma Reports Acceptance Into National Institutes Of Health Commercialization Accelerator Program

Financial news for NAVB dated on 2018-08-17: Stocks Which Set New 52-Week Low Yesterday, August 16th

Financial news for NAVB dated on 2018-08-16: Stocks Which Set New 52-Week Low Yesterday, August 15th

Financial news for NAVB dated on 2018-08-15: Navidea Biopharmaceuticals Receives Listing Noncompliance Notice from NYSE

Financial news for NAVB dated on 2018-08-08: Navidea Biopharmaceutical Q2 EPS \$(0.02), Same YoY, Sales \$542.127M Up From \$611.599K YoY

Financial news for NAVB dated on 2018-05-08: Navidea Biopharmaceutical Q1 EPS \$(0.04), Made \$276.445K Sales

Financial news for NAVB dated on 2018-04-16: Navidea Biopharma Reports Deal To Sublicense NAV4694 Global Development Rights

Financial news for NAVB dated on 2018-03-08: Navidea Biopharmaceuticals Reports Q4 EPS \$(0.03) vs \$(0.02) In Prior Year Period, Sales \$395K vs \$1.03M In Prior Year Period

Financial news for NAVB dated on 2018-02-23: Navidea Biopharma 8-K Shows Co. Entered Settlement Deal With Sinotau; Both Cos. Agreed To Stipulate To The Voluntarily Dismissal Of All Claims, No Other Terms Disclosed

Financial news for NAVB dated on 2017-11-07: Navidea Biopharma Reports Q3 EPS \$(0.01) vs. \$0.00 In Same Qtr. Last Year, Sales \$224K vs. \$1.8M YoY

Financial news for NAVB dated on 2017-06-12: Navidea Reports Launch Of LYMPHOSEEK In Europe

Financial news for NAVB dated on 2017-05-16: UPDATE: Navidea Says Paid to Ricardo Gonzalez Total of ~\$617.88K

Financial news for NAVB dated on 2017-05-16: 8-K from Navidea Shows Co. Received Ruling In Favor of Ricardo Gonzalez, Finding He Was Terminated by Co. Without Cause

Financial news for NAVB dated on 2017-05-09: Navidea Biopharmaceuticals Reports Q1 EPS \$0.52 vs \$(0.02) In Prior Year Period

Financial news for NAVB dated on 2017-03-29: Navidea Reports Q4 EPS \$(0.02) vs \$(0.02) in Same Qtr. Last Year, Sales \$3.4M

Financial news for NAVB dated on 2017-03-16: Navidea Biopharma Files Non-Timely 10-K

Financial news for NAVB dated on 2017-02-23: Navidea Shares Resume Trade

Financial news for NAVB dated on 2017-02-23: Navidea Biopharmaceuticals and Subsidiary Macrophage Therapeutics To Pay CRG \$59M In Payments Of Amounts Owning Pursuant To Previous Loan Documents

Financial news for NAVB dated on 2017-02-23: Navidea 8-K Filing Just Out

Financial news for NAVB dated on 2017-02-23: Navidea Shares Halted News Pending

Financial news for NAVB dated on 2016-11-25: 12 Biggest Mid-Day Gainers For Friday

Financial news for NAVB dated on 2016-11-25: Mid-Day Market Update: Crude Oil Down 3.5%; Navidea Shares Spike Higher

Financial news for NAVB dated on 2016-11-25: Mid-Morning Market Update: Markets Open Higher; Ctrip.Com To Acquire Skyscanner

Financial news for NAVB dated on 2016-11-25: Navidea Biopharma +40% Premarket @\$1.12; Co Announced Asset Purchase Agreement with Cardinal Health on Wednesday

Financial news for NAVB dated on 2016-11-23: Navidea Biopharma Resumes Trading, Now Up 4.59%

Financial news for NAVB dated on 2016-11-23: UPDATE: Navidea Will Receive \$80M From Cardinal Health At Closing And Potential To Earn Up To \$230M Based On Certain Milestones Through 2026

Financial news for NAVB dated on 2016-11-23: Navidea Signs Asset Purchase Agreement with Cardinal Health

Financial news for NAVB dated on 2016-11-23: Navidea Biopharmaceuticals Inc Shares Halted News Pending

Financial news for NAVB dated on 2016-11-03: Navidea Reports Q3 EPS Breakeven vs. Est. \$(0.02), Rev. \$8.49M vs. Est. \$6.47M

Financial news for NAVB dated on 2016-09-26: Navidea Names Michael Goldberg Pres, CEO; Eric Rowinsky Named Chair

Financial news for NAVB dated on 2016-09-06: Benzinga's M&A Chatter for Tuesday September 6, 2016

Financial news for NAVB dated on 2016-09-06: Navidea Biopharmaceuticals to Hold Investor Update Call on Wednesday Sep 7 @8:30 AM ET

Financial news for NAVB dated on 2016-09-06: Mid-Afternoon Market Update: Gold Futures Up 2%; CoLucid Shares Climb After Migraine Drug Achieves Primary And Key Secondary Endpoints

Financial news for NAVB dated on 2016-09-06: 12 Biggest Mid-Day Gainers For Tuesday

Financial news for NAVB dated on 2016-09-06: Mid-Day Market Update: Navistar Rises After Strategic Alliance With Volkswagen Truck & Bus; Tonix Shares Drop

Financial news for NAVB dated on 2016-09-06: 15 Stocks Moving In Tuesday's Pre-Market Session

Financial news for NAVB dated on 2016-09-06: Navidea Biopharma +64.71% Premarket

@\$0.56; Co Announced LoI to Sell Lymphoseek in North America to Cardinal Health

Financial news for NAVB dated on 2016-09-06: Navidea Biopharma Announces Letter of Intent to Sell Lymphoseek in North America to Cardinal Health for \$80M and Up to \$310M

Financial news for NAVB dated on 2016-08-10: Navidea Biopharmaceuticals Files for Non-Timely 10-Q

Financial news for NAVB dated on 2016-08-04: Navidea Reports Q2 EPS \$(0.04) vs. Est. \$(0.03), Rev. \$5.394M vs. Est. \$5.24M

Financial news for NAVB dated on 2016-07-19: Navidea Reports Received IRB Approval for Lymphoseek RA Protocol

Financial news for NAVB dated on 2016-06-16: Navidea announces positive study results for Lymphoseek studies; positive comparative results versus commonly-used, non-receptor-targeted imaging agents

Financial news for NAVB dated on 2016-06-02: UPDATE: Navidea Reiterates Firmly Held Position Alleged Claims Do Not Constitute Events of Default Under Loan Deal

Financial news for NAVB dated on 2016-06-02: 8-K from Navidea Shows Co. Continues to Explore Financing Arrangements In Order to Refinance CRG Debt

Financial news for NAVB dated on 2016-05-26: Navidea Biopharma Awarded Fast-Track SBIR Grant Funds Of Potentially \$1.8M To Be Released in 3 Parts Over 2.5 Years With Goal Of Completing IND Submission For Manocept Construct

Financial news for NAVB dated on 2016-05-26: Navidea Biopharma Reports Won \$1.8M Fast-Track NIH SBIR Grant for Manocept's Evaluation in Kaposi's Sarcoma

Financial news for NAVB dated on 2016-05-26: UPDATE: Navidea Shares Halted with News Pending

Financial news for NAVB dated on 2016-05-26: Navidea Biopharma Shares Halted

Financial news for NAVB dated on 2016-05-23: 12 Stocks Moving In Monday's Pre-Market Session

Financial news for NAVB dated on 2016-05-23: Navidea Announces Unsolicited Offer to Refinance CRG Loan

Financial news for NAVB dated on 2016-05-17: Navidea Q1 EPS (\$0.02) vs (\$0.03) est, Revenue \$4.7M vs \$4.7M est

Financial news for NAVB dated on 2016-05-10: Navidea Biopharmaceuticals Files Non-Timely 10@

Financial news for NAVB dated on 2016-04-26: Navidea Names Jed Latkin as Interim Chief Operating Officer

Financial news for NAVB dated on 2016-04-15: Here's Why Navidea Biopharmaceuticals Surged 25%

Financial news for NAVB dated on 2016-04-15: Navidea, Macrophage Offer Business Update

Financial news for NAVB dated on 2016-04-06: 8-K from Navidea Biopharma Shows Michael Goldberg Named Chair

Financial news for NAVB dated on 2016-04-04: Navidea Offers Update on Clinical Development Plan for Diagnostic Use of Lymphoseek IV in RA

Financial news for NAVB dated on 2016-03-23: Navidea Sees FY 2016 Revenue \$23M to \$25M vs \$24.3M est

Financial news for NAVB dated on 2016-03-23: Earnings Scheduled For March 23, 2016

Financial news for NAVB dated on 2016-02-11: Navidea Biopharmaceuticals Enrolls First Patient in Fast Track Granted Cervical Cancer Study of Lymphoseek(r)

Financial news for NAVB dated on 2016-02-02: Navidea Sees FY15 Lymphoseek Sales To Navidea Of \$10.2M

Financial news for NAVB dated on 2016-02-02: UPDATE: Navidea '15 Commercial Highlights: Total Brand Sales ~\$20M, Nearly Tripled Number of Accounts Which Averaged 20+ Doses/Month

Financial news for NAVB dated on 2016-02-02: Navidea Issues Update on Lymphoseek, Immunodiagnostics Development Pipeline

Financial news for NAVB dated on 2015-12-10: Lymphoseek(r) Technically Successful in Evaluation of Sentinel Lymph Node Biopsy in Patients Undergoing Neoadjuvant Chemotherapy

Financial news for NAVB dated on 2015-12-04: US Stock Futures Surge; All Eyes On Jobs Report

Financial news for NAVB dated on 2015-12-04: Navidea Biopharmaceuticals Announces Positive Lymphoseek Results

Financial news for NAVB dated on 2015-09-02: Navidea Biopharmaceuticals Announces Dual Listing on Tel Aviv Stock Exchange

Financial news for NAVB dated on 2015-08-24: Navidea Biopharma Announces Will Register Shares for Dual Listing on Tel-Aviv Exchange

Financial news for NAVB dated on 2015-08-20: Navidea Reports Publication of Lymphoseek Results: Showed Lymphoseek Minimized Patients Discomfort While Allowing For Effective SLN Mapping

Financial news for NAVB dated on 2015-07-30: Navidea Biopharma Reports Q2 Loss \$0.06 Vs Est Loss \$0.04, Sales \$2.87M vs Est \$2.18M

Financial news for NAVB dated on 2015-07-02: Macrophage Therapeutics Reports Data Demonstrating a Manocept(tm) Drug Conjugate Induces Apoptosis in CD206 Positive Kaposi's Sarcoma and Tumor Associated Macrophages

Financial news for NAVB dated on 2015-07-02: Navidea Announces Clinical Data for Manocept Shows Agent Localizes in Multiple KS Lesions

Financial news for NAVB dated on 2015-06-11: BIND Therapeutics, Navidea's Macrophage Report Collab for Engineering CD206 Target Accurin Nanoparticle Using Manocept Macrophage Targeting Platform

Financial news for NAVB dated on 2015-06-11: Navidea Announces Manocept Study Results in Rheumatoid Arthritis to be Presented at EULAR '15 ECR

Financial news for NAVB dated on 2015-06-08: Navidea Reports Positive Lymphoseek Comparative Results in Injection Site Pain Study in Breast Cancer

Financial news for NAVB dated on 2015-05-12: Navidea Reports Q1 Sales \$2.1M vs \$2.11M Est., Loss of \$0.05/Share vs Loss of \$0.03/Share Est.

Financial news for NAVB dated on 2015-05-11: Navidea Secures \$60M Loan With CRG to Support Lymphoseek Commercialization, Advancement of Development Pipeline

Financial news for NAVB dated on 2015-04-27: Navidea Biopharm Enters Agreement With Alseres to Terminate NAV5001 Sub-License Agreement

Financial news for NAVB dated on 2015-04-22: Navidea Offers Data for Manocept CD206 Targeting Platform Shows Potential to Impact Tumor-Associated Macrophages, Kaposi's Sarcoma Tumor Cells

Financial news for NAVB dated on 2015-03-05: Morning Market Gainers

Financial news for NAVB dated on 2015-03-05: Benzinga's Top #PreMarket Gainers

Financial news for NAVB dated on 2015-03-05: CORRECTION: Navidea Biopharm Reported Q3 Revenues Of \$2.2B Vs Est \$2.10

Financial news for NAVB dated on 2015-03-05: Navidea Biopharm Reports Q3 EPS -\$0.08 Vs Est -\$0.05, Sales \$2.2M Vs Est \$2.10

Financial news for NAVB dated on 2015-03-05: UPDATE Navidea May Receive Additional Milestone Payments Up to \$5M, Royalties on Net Sales in Europe

Financial news for NAVB dated on 2015-03-05: Navidea Awarded \$2M Partnership With Norgine For Lymphoseek Partnership

Financial news for NAVB dated on 2015-02-09: Gilead's Sofosbuvir Just Made Achillion Investors Very Happy

Financial news for NAVB dated on 2015-02-09: UPDATE: Navidea Reports Prelim. FY14 Sales \$6.3M vs \$6.2M Est.

Financial news for NAVB dated on 2015-02-09: Navidea Reports Prelim. Q4 Sales \$2.2M

vs \$2.1M Est.

Financial news for NAVB dated on 2014-12-15: Navidea's Macrophage Therapeutics Announces Data Of Manocept Platform Compound Tilmanocept

Financial news for NAVB dated on 2014-12-15: Navidea Biopharma Shares Resume Trading, Now +6%

Financial news for NAVB dated on 2014-12-15: Data Presented by Independent Academic Collaborators Demonstrate Ability of Novel Manocept Immunotherapy to Kill Activated Macrophages from KS Patients

Financial news for NAVB dated on 2014-12-15: Navidea Biopharma Shares Indicated with Opening Delay Amid Code News Pending

Financial news for NAVB dated on 2014-11-20: European Commission Approves Navidea's Sentinel Lymph Node Detection Agent Lymphoseek

Financial news for NAVB dated on 2014-11-17: Navidea Biopharmaceuticals Director Goldberg Buys 100,000 Shares @\$1.08/Share -Form 4

Financial news for NAVB dated on 2014-11-12: Navidea Biopharmaceuticals Director Ford Buys 10,000 Shares @\$1.03 -Form 4

Financial news for NAVB dated on 2014-11-11: Navidea Receives \$1.1M PDUFA Filing Fee Refund For Award Of Orphan Drug Status; Platinum Partners Reaffirms Commitment To Line Of Credit

Financial news for NAVB dated on 2014-10-15: Navidea Announces Rick Gonzalez As New CEO

Financial news for NAVB dated on 2014-10-15: FDA Approves Expanded Navidea's Lymphoseek for Lymphatic Mapping in Solid Tumors

Financial news for NAVB dated on 2014-09-26: Navidea Reports CHMP Recommended European Approval for Lymphoseek

Financial news for NAVB dated on 2014-09-23: Navidea Awarded \$1.6M Grant

Financial news for NAVB dated on 2014-09-18: Navidea Receives Orphan Drug Designation From FDA For Use Of Lymphoseek(R) In Head And Neck Cancers

Financial news for NAVB dated on 2014-09-10: Agilis Biotherapeutics Names Dr. Mark Pykett AS CEO

Financial news for NAVB dated on 2014-08-06: Navidea Biopharmaceuticals, Inc. Reports Q2 EPS of \$(0.07), Inline

Financial news for NAVB dated on 2014-07-16: Navidea Joins Essex Woodland's Rheumco, Will Develop Radiopharmaceuticals To Detect And Treat Arthritic Diseases

Financial news for NAVB dated on 2014-06-16: From Navidea 8K: Changest R&D Expanxe To Less Than \$20M For 2014, From \$25-50M

Financial news for NAVB dated on 2014-06-13: FDA Has Approved Navidea's Lymphoseek for Helping Determine Extent of Head, Neck Cancer in Body

Financial news for NAVB dated on 2014-06-11: Navidea Reports Results from Post-Hoc Analysis of Phase 3 Clinical Trial of NEO3-06, Shows Preferential Accumulation in Tumor-Positive Sentinel Lymph Nodes

Financial news for NAVB dated on 2014-06-10: UPDATE: Navidea Biopharma Announces Positive Lymphoseek Injection Results

Financial news for NAVB dated on 2014-06-10: Navidea Biopharma Announces Positive Lymphoseek Injection Results

Financial news for NAVB dated on 2014-05-19: UPDATE: JMP Securities Reiterates On Navidea Biopharmaceuticals On Pipeline Restructuring

Financial news for NAVB dated on 2014-05-15: Navidea Announces Restructuring of Pipeline Development; Michael Goldberg Appointed Interim CEO

Financial news for NAVB dated on 2014-05-08: Navidea Biopharma Files \$100M Mixed Securities Shelf

Financial news for NAVB dated on 2014-05-07: Navidea Biopharmaceuticals, Inc. Reports Q1 EPS of \$(0.08) vs \$(0.10) Est

Financial news for NAVB dated on 2014-05-07: Navidea Biopharmaceuticals, Inc. Reports Q1 EPS of \$(0.08) vs \$(0.10) Est

Financial news for NAVB dated on 2014-04-17: Navidea Provides Updates on Lymphoseek Programs

Financial news for NAVB dated on 2014-04-10: Navidea Announces Presentation of Study Findings of Manocept Platform Imaging Agent in Kaposi Sarcoma at AACR Annual Meeting

Financial news for NAVB dated on 2014-03-19: UPDATE: Navidea Believes Course of Review Continues to be Supportive of Market Development Plans, Outlook for Revenue Generation In Europe Beginning In 2015

Financial news for NAVB dated on 2014-03-19: UPDATE: Navidea Biopharma Offers Update on EMA Application For Lymphoseek, Sets Second sNDA PDUFA Target Date Oct. 16th

Financial news for NAVB dated on 2014-03-19: Navidea Biopharmaceuticals Provides Update on EMA Application For Lymphoseek

Financial news for NAVB dated on 2014-03-14: Navidea Biopharma Announces Presentation of Lymphoseek Three-Year Recurrence, Survival Outcomes, Says Disease-Specific Survival Rate 98.6%

Financial news for NAVB dated on 2014-03-06: Morning Gainers for Mar. 6, 2014: PXLW, SGMO, ERII, RGSE, NAVB, PSTI

Financial news for NAVB dated on 2014-03-06: Navidea BioPharma Closes \$30M Loan with Oxford Finance, Issued Warrants for 391K Shares at \$1.92/Share, Will Use Proceeds for Lymphoseek Commercialization

Financial news for NAVB dated on 2014-03-05: Morning Movers for Mar. 5, 2014: FCEL, ARWR, SWHC, CPST Moving Higher

Financial news for NAVB dated on 2014-02-18: Navidea Announces FDA Sets Target Review Date for Lymphoseek sNDA of June 16, 2014

Financial news for NAVB dated on 2014-01-13: Form S-3 from Navidea Biopharma Shows Registration for Up to 100K Shares for Selling Holders

Financial news for NAVB dated on 2014-01-07: Navidea Biopharma Expands Lymphoseek Global Distribution Pact to Taiwan

Financial news for NAVB dated on 2013-12-19: Navidea Announces EMA Continues Marketing Authorization Application Review for Lymphoseek

Financial news for NAVB dated on 2013-12-17: Navidea Biopharma Submits sNDA for Lymphoseek for Sentinel Lymph Node Detection in Patients with Head, Neck Cancer

Financial news for NAVB dated on 2013-12-10: Navidea Announces FDA Fast Track Designation for Lymphoseek for Sentinel Lymph Node Detection in Patients with Head, Neck Cancer

Financial news for NAVB dated on 2013-11-29: Option Alert: Navidea Biopharmaceuticals January \$3 Call; 10,231 Contracts Traded Friday vs 22,242 Open Interest; Currently \$1.61

Financial news for NAVB dated on 2013-11-26: Navidea Biopharma Reports Collaboration with University of Alabama-Birmingham on Clinical Study Evaluating RIGS Agent

Financial news for NAVB dated on 2013-11-14: Navidea Biopharmaceuticals Awarded New US Patent for NAV5001

Financial news for NAVB dated on 2013-11-13: UPDATE: Aegis Capital Reiterates on Navidea Biopharmaceuticals Following 3Q 2013 Earnings Report

Financial news for NAVB dated on 2013-11-13: Navidea Will Collaborate with University of California - San Francisco on Clinical Study Evaluating Manocept Platform

Financial news for NAVB dated on 2013-11-11: Navidea Biopharmaceuticals Rises 6.5%; May be Attributed to Seeking Alpha Post

Financial news for NAVB dated on 2013-10-29: Stocks Hitting 52-Week Lows

Financial news for NAVB dated on 2013-09-24: Navidea Biopharma Files Prospectus for 10.6M Shares, Warrants Up to 3.2M

Financial news for NAVB dated on 2013-09-19: Navidea Says Lymphoseek Met Primary Endpoint in NEO3-06 Trial, Looking to File sNDA by Year End

Financial news for NAVB dated on 2013-09-12: Navidea Biopharma, Osobio Report Manufacturing Services Pact in Form 8-K

Financial news for NAVB dated on 2013-08-22: US Stock Futures Up Ahead Of Jobless Claims

Financial news for NAVB dated on 2013-08-22: Navidea Biopharmaceuticals Announces Agreement with FDA on Special Protocol Assessments for NAV5001 Phase 3 Program

Financial news for NAVB dated on 2013-08-07: Navidea Biopharmaceuticals, Inc. Reports Q2 EPS of \$(0.09) vs \$(0.06) Est; Revenue of \$195.28K vs \$530.0K Est

Financial news for NAVB dated on 2013-07-22: Navidea Biopharmaceuticals Highlights New Data for NAV4694 PET b-Amyloid Imaging Agent Presented at AAIC 2013

Financial news for NAVB dated on 2013-07-16: Navidea Biopharmaceuticals' NAV4694 b-Amyloid Imaging Agent to Be Used in Alzheimer's Disease Studies by Australian Imaging

Financial news for NAVB dated on 2013-07-15: Navidea Biopharmaceuticals Announces Board Member Resignation

Financial news for NAVB dated on 2013-06-26: Navidea Biopharmaceuticals Closes \$25M Debt Financing with GE Capital, Healthcare Financial Services

Financial news for NAVB dated on 2013-06-12: Navidea Biopharmaceuticals Announces Results from Lymphoseek(r) Study on Accuracy of Lymph Node Detection from Injection Time to Surgery; Working with FDA on Evaluating SNDA Submission

Financial news for NAVB dated on 2013-06-11: Navidea Biopharmaceuticals Announces Results from Lymphoseek(R) Study on Accuracy of Lymph Node Detection from Injection Time to Surgery

Financial news for NAVB dated on 2013-06-10: Navidea Says Lymphoseek Results Statistically Significant, Results Unveiled at SNMMI

Financial news for NAVB dated on 2013-06-04: Navidea Announces Data Presentations at 2013 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI)

Financial news for NAVB dated on 2013-05-29: Navidea Biopharma Issues Highlights of Lymphoseek Data at JIOC

Financial news for NAVB dated on 2013-05-15: Navidea Biopharma Announces Manufacturing, Supply Deal with Nordion

Financial news for NAVB dated on 2013-05-08: Navidea Biopharmaceuticals, Inc. Reports Q1 EPS of \$(0.06) vs \$(0.07) Est

Financial news for NAVB dated on 2013-05-01: Navidea Announces Launch of Lymphoseek in US

Financial news for NAVB dated on 2013-04-24: Navidea Biopharma Reports Underwritten Sale of Common Stock

Financial news for NAVB dated on 2013-04-09: Janney Capital Initiates Coverage on Navidea Biopharmaceuticals, Inc. at Buy, Announces \$5.00 PT

Financial news for NAVB dated on 2013-04-09: Mid-Day Market Update: Markets Heading Upwards, MGIC Investment Drops

Financial news for NAVB dated on 2013-04-04: Navidea Biopharma Reports Top-Line Results from Interim Analysis of Lymphoseek Phase 3 Trial

Financial news for NAVB dated on 2013-03-27: Navidea Biopharmaceuticals Announces Enrollment of First Subject in Phase 2b Trial of NAV4694 in Subjects with Mild Cognitive Impairment (MCI)

Financial news for NAVB dated on 2013-03-26: 13 Drugs Pending FDA Approval in 2013

Financial news for NAVB dated on 2013-03-21: Results of Lymphoseek Phase 3 Clinical Trials in Breast Cancer Published in Annals of Surgical Oncology

Financial news for NAVB dated on 2013-03-13: Navidea BioPharma Will Hold Call to Discuss Lymphoseek FDA Approval at 4PM EST Today

Financial news for NAVB dated on 2013-03-13: Navidea BioPharma Shares Now Sinking Following Initial Knee-Jerk Higher, Stock Now Down 10%

Financial news for NAVB dated on 2013-03-13: Navidea Biopharmaceuticals Spikes Higher

on FDA Approval of Lymphoseek

Financial news for NAVB dated on 2013-03-13: FDA Approves Navidea BioPharma's Lymphoseek

Financial news for NAVB dated on 2013-03-06: Navidea Biopharmaceuticals, Inc. Reports Q4 EPS of \$(0.07) vs \$(0.08) Est

Financial news for NAVB dated on 2013-03-06: UPDATE: Piper Jaffray Initiates Navidea Biopharmaceuticals with Underweight Rating on Innovative Pipeline

Financial news for NAVB dated on 2013-03-05: Piper Jaffray Initiates Coverage on Navidea Biopharmaceuticals, Inc. at Underweight, Announces \$1.50 PT

Financial news for NAVB dated on 2013-02-04: Navidea to Collaborate with Maimonides Medical Center on Trial Utilizing Lymphoseek for Lymphatic Mapping in Colorectal Cancer

Financial news for NAVB dated on 2013-01-30: Navidea BioPharma Sold 1,542,389 Shares at \$3.10/Share

Financial news for NAVB dated on 2013-01-22: UPDATE: Aegis Capital Initiates Navidea Biopharmaceuticals at Hold

Financial news for NAVB dated on 2013-01-22: Aegis Capital Initiates Coverage on Navidea Biopharmaceuticals, Inc. at Hold, Announces \$3.00 PT

Financial news for NAVB dated on 2013-01-22: Burrill Initiates Coverage on Navidea Biopharmaceuticals, Inc. at Outperform, Announces \$5.00 PT

Financial news for NAVB dated on 2013-01-03: Navidea BioPharma Offers Interim Analysis Point of Phase 3 Head, Neck Cancer Study of Lymphoseek

Financial news for NAVB dated on 2012-12-18: Navidea Submits Lymphoseek Marketing Application in Europe

Financial news for NAVB dated on 2012-11-26: Navidea to Present Data from Lymphoseek Studies at RSNA, CTRC-AACR Meetings

Financial news for NAVB dated on 2012-11-13: Navidea BioPharma Says PDUFA Goal Date for Lymphoseek April 30, 2013

Financial news for NAVB dated on 2012-10-10: Navidea Biopharmaceuticals Announces the Presentation of Lymphoseek Data at Upcoming Scientific Meetings in October

Financial news for NAVB dated on 2012-09-11: Morning Market Losers

Financial news for NAVB dated on 2012-09-11: Benzinga's Top Pre-Market Losers

Financial news for NAVB dated on 2012-09-10: Navidea Biopharmaceuticals Falls 35% After-Hours on FDA Complete Response Letter

Financial news for NAVB dated on 2012-09-10: Navidea Biopharmaceuticals Receives Complete Response Letter from FDA for Lymphoseek

Financial news for NAVB dated on 2012-09-10: Navidea Pharma Receives FDA Response Letter Due to Lymphoseek Manufacturing Deficiencies

Financial news for NAVB dated on 2012-09-10: UPDATE: Navidea Biopharmaceuticals off Lows Following Bear Raid

Financial news for NAVB dated on 2012-09-10: Navidea Biopharmaceuticals Spikes Lower

Financial news for NAVB dated on 2012-07-31: Navidea Biopharmaceuticals Completes License for Parkinson's Disease Imaging Agent

Financial news for NAVB dated on 2012-07-23: Head-to-Head Study Comparing Navidea's AZD4694 to the Gold Standard for Imaging Beta Amyloid Protein Deposits Presented at Alzheimer's Association International Conference

Financial news for NAVB dated on 2012-07-18: Biotechs With Upcoming PDUFA Dates

Financial news for NAVB dated on 2012-06-26: Navidea Biopharmaceuticals Elects to Extend Evaluation Period for Option to License Parkinson's Disease Imaging Agent

Financial news for NAVB dated on 2012-06-04: Meta-analysis of Navidea Biopharmaceuticals Lymphoseek(r) Phase 3 Data Compared to Standard of Care Techniques Published in Conjunction with the ASCO Annual Meeting

Financial news for NAVB dated on 2012-05-29: Presentation Highlights Clinical Potential of Navidea Biopharmaceuticals' b-Amyloid Imaging Biomarker AZD4694

Financial news for NAVB dated on 2012-04-03: Navidea: FDA Extends PDUFA Date for Lymphoseek by Three Months

Financial news for NAVB dated on 2012-03-28: Navidea Biopharmaceuticals Announces Presentation of Lymphoseek(r) Phase 3 Data at Society of Surgical Oncology Meeting

Financial news for NAVB dated on 2012-02-08: Option Alert: Navidea Biopharmaceuticals January 2013 5 Call; Block Trade, 4,900 Contracts

Financial news for NAVB dated on 2012-02-06: Rodman & Renshaw Reiterates Outperform, \$7 Target on Navidea Biopharmaceuticals

Financial news for NAVB dated on 2012-02-01: Navidea Obtains Positive EMA Guidance for Lymphoseek; Company to Submit Marketing Authorization Application in Europe

Financial news for NAVB dated on 2012-01-26: LifeTech Capital Maintains Strong Speculative Buy on Navidea After Alseres Agreement

Financial news for NAVB dated on 2012-01-25: Navidea Biopharmaceuticals Enters into Option Agreement to License Parkinson's Disease Imaging Agent

Financial news for NAVB dated on 2012-01-20: Option Alert: Navidea Biopharmaceuticals January 2013 3 Call; Block Trade, 4,939 Contracts